Pharmaceutical - UK

Filter

Current filters:

UK

Popular Filters

1 to 25 of 305 results

Milestone for GSK/NIH candidate Ebola vaccine as first doses shipped for Phase III trial

Milestone for GSK/NIH candidate Ebola vaccine as first doses shipped for Phase III trial

23-01-2015

UK pharma major GlaxoSmithKline said this morning that the first batch of its candidate Ebola vaccine…

EbolaGlaxoSmithKlinePharmaceuticalResearchUKVaccines

UK’s NICE backs Bayer’s Xarelto for reducing risk of secondary events in ACS

UK’s NICE backs Bayer’s Xarelto for reducing risk of secondary events in ACS

23-01-2015

The National Institute for Health and Care Excellence (NICE), the health costs watchdog for England,…

BayerCardio-vascularPharmaceuticalPricingRegulationUKXarelto

NICE set to recommend Boehringer’s type 2 diabetes drug Jardiance

NICE set to recommend Boehringer’s type 2 diabetes drug Jardiance

22-01-2015

England’s health care costs watchdog the National Institute for Health and Care Excellence (NICE) has…

Boehringer IngelheimDiabetesJardiancePharmaceuticalPricingRegulationUK

Novo Nordisk's Victoza granted label extension in the UK

Novo Nordisk's Victoza granted label extension in the UK

20-01-2015

A license extension has been granted in the UK for Victoza (liraglutide) from Danish insulin giant Novo…

Nephrology and HepatologyNovo NordiskPharmaceuticalRegulationUKVictoza

England's cancer outcomes worse than rest of Europe: National Audit Office report

England's cancer outcomes worse than rest of Europe: National Audit Office report

16-01-2015

The UK’s National Audit Office has published a report, Progress in improving cancer services and outcomes…

Markets & MarketingOncologyPharmaceuticalPoliticsPricingResearchUK

Boehringer opts to take up rights to Oxford BioThera’s oncology target

Boehringer opts to take up rights to Oxford BioThera’s oncology target

14-01-2015

Privately-held, UK-based Oxford BioTherapeutics says that German family-owned pharma major Boehringer…

Boehringer IngelheimLicensingOncologyOxford BioTherapeuticsPharmaceuticalUK

NHS England raises budget for Cancer Drugs Fund but axes some products

NHS England raises budget for Cancer Drugs Fund but axes some products

13-01-2015

As has been widely expected and already much criticized, England’s over-stretched Cancer Drugs Fund…

FinancialHealthcareOncologyPharmaceuticalUK

GW and Otsuka report Sativex failed to meet primary endpoint in cancer pain

GW and Otsuka report Sativex failed to meet primary endpoint in cancer pain

09-01-2015

UK-based GW Pharmaceuticals and Japanese drugmaker Otsuka have reported that Sativex (nabiximols) did…

AnalgesiaGW PharmaceuticalsOncologyOtsuka PharmaceuticalPharmaceuticalResearchSativexUKUSA

Shield Therapeutics' MAA for Ferracru accepted for review by EMA

Shield Therapeutics' MAA for Ferracru accepted for review by EMA

07-01-2015

Independent UK pharma company Shield Therapeutics has received acceptance for review of the Marketing…

FerracruHematologyPharmaceuticalRegulationShield TherapeuticsUK

UK’s NICE says cost of Celgene’s Abraxane is not justified by its limited benefit

UK’s NICE says cost of Celgene’s Abraxane is not justified by its limited benefit

30-12-2014

UK health care cost watchdog the National Institute for Health and Care Excellence (NICE) has today published…

AbraxaneCelgene CorpOncologyPharmaceuticalRegulationUK

Verona Pharma appoints Kenneth Newman to newly-created chief medical officer position

Verona Pharma appoints Kenneth Newman to newly-created chief medical officer position

18-12-2014

Respiratory disease specialist Verona Pharma has appointed Kenneth Newman to the newly-created chief…

BoardroomPharmaceuticalRespiratory and PulmonaryUKVerona Pharma

NICE backs Pradaxa for treating and preventing potentially fatal blood clots

NICE backs Pradaxa for treating and preventing potentially fatal blood clots

17-12-2014

In final guidance published today, UK health cost watchdog the National Institute for Health and Care…

Boehringer IngelheimCardio-vascularPharmaceuticalPradaxaPricingRegulationUK

UK’s NICE recommends Pfizer’s Inlyta for kidney cancer

UK’s NICE recommends Pfizer’s Inlyta for kidney cancer

16-12-2014

UK health costs watchdog the National Institute for Health and Care Excellence (NICE) has issued new…

InlytaOncologyPfizerPharmaceuticalPricingRegulationUK

UK NICE partially backs Bayer’s Xofigo in preliminary assessment

UK NICE partially backs Bayer’s Xofigo in preliminary assessment

15-12-2014

UK health costs watchdog the National Institute for Health and Care Excellence (NICE) have recommended…

BayerOncologyPharmaceuticalPricingRegulationUKXofigo

NICE says ‘yes’ to Remicade, Humira and Simponi for ulcerative colitis

NICE says ‘yes’ to Remicade, Humira and Simponi for ulcerative colitis

12-12-2014

UK health care cost watchdog the National Institute for Health and Care Excellence (NICE) has issued…

AbbVieGastro-intestinalsHumiraMerck & CoPharmaceuticalPricingRegulationRemicadeSimponi InjectionUK

Twin Swedish and Welsh life sciences hubs plan to share knowledge

Twin Swedish and Welsh life sciences hubs plan to share knowledge

12-12-2014

A Swedish cluster for life sciences, Medicon Village, visited the new Life Sciences Hub Wales center…

Medicon VillagePharmaceuticalResearchSwedenUK

Alzheimer's Research UK launches $31 million global clinical trials fund

Alzheimer's Research UK launches $31 million global clinical trials fund

12-12-2014

Alzheimer’s Research UK, the country’s leading dementia research charity, has launched a global clinical…

DementiaNeurologicalPharmaceuticalResearchUK

UK industry makes third quarter PPRS payment, Department of Health sets 2015 percentage at 10.36%

UK industry makes third quarter PPRS payment, Department of Health sets 2015 percentage at 10.36%

11-12-2014

The UK pharma industry has made its third quarter payment to underwrite the growth of the medicines bill…

ABPIDepartment of HealthPharmaceuticalRegulationUK

Recently-announced timeline of UK Patent Box changes helps address uncertainty, says patent attorney

04-12-2014

Following UK Chancellor of the Exchequer George Osborne’s confirmation of an overhaul of the Patent…

FinancialPatentsPharmaceuticalResearchUK

ABPI welcomes Chancellor’s decision to increase rate of R&D tax credits

04-12-2014

In his Autumn Statement yesterday, UK Chancellor of the Exchequer, George Osborne said he wants to help…

FinancialPharmaceuticalResearchUK

UK Prime Minister to announce £15 million dementia research fund in Autumn Statement

UK Prime Minister to announce £15 million dementia research fund in Autumn Statement

02-12-2014

The UK prime minister David Cameron is to announce a £15 million ($24 million) commitment to a new fund…

NeurologicalPharmaceuticalPoliticsResearchUK

FDA accepts NDA filing from AstraZeneca for Iressa

FDA accepts NDA filing from AstraZeneca for Iressa

02-12-2014

The US Food and Drug Administration has accepted for filing the New Drug Application from Iressa (gefitinib)…

AstraZenecaIressaOncologyPharmaceuticalRegulationUK

1 to 25 of 305 results

COMPANY SPOTLIGHT

Parexel

Parexel

Back to top